TuisAIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
Vorige sluiting
$0,14
Dagwisseling
$0,12 - $0,14
Jaarwisseling
$0,12 - $0,62
Markkapitalisasie
8,27 m USD
Gemiddelde volume
1,32 m
P/V-verhouding
-
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 35,00 k | -23,91% |
Bedryfskoste | 4,52 m | -44,74% |
Netto inkomste | -3,70 m | 52,66% |
Netto winsgrens | -10,57 k | 37,78% |
Wins per aandeel | -0,07 | 57,39% |
EBITDA | -4,43 m | 45,38% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 7,20 m | -67,89% |
Totale bates | 13,59 m | -51,23% |
Totale aanspreeklikheid | 10,68 m | 103,00% |
Totale ekwiteit | 2,91 m | — |
Uitstaande aandele | 63,71 m | — |
Prys om te bespreek | 2,80 | — |
Opbrengs op bates | -76,60% | — |
Opbrengs op kapitaal | -142,29% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -3,70 m | 52,66% |
Kontant van bedrywe | -3,11 m | 45,16% |
Kontant van beleggings | 334,00 k | 199,40% |
Kontant van finansiering | 137,00 k | -41,20% |
Netto kontantverandering | -2,64 m | 54,30% |
Beskikbare kontantvloei | -2,11 m | 34,80% |
Meer oor
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Gestig
1966
Webwerf
Werknemers
27
